CSL Vifor has said it is prepared to carry out a “comprehensive and multi-channel communication campaign” to address allegations by the EU that it disparaged one of its co
Vifor Pharma and Cara Therapeutics' Kapruvia has become the first drug to be approved in the EU to treat one of the most common and challenging side effects for people undergoing dialysis f
Australian biotech group CSL has agreed a deal to acquire Swiss drugmaker Vifor Pharma in an all-cash deal that expands its speciality medicines business.
On the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by acquiring Spain's Sanifit and fellow Swiss biotech Inositec for a combined value of €2
Vifor Pharma and partner Angion Biomedica have suffered another setback with their drug to prevent organ damage, this time in high-risk kidney transplant patients.
One of the most common and challenging side effects for people undergoing dialysis for chronic kidney disease – chronic itching – now has an FDA-approved treatment.
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.